Indivior Pharmaceuticals, Inc. (INDV) FY2026 YTD Q3 Statement of Cash Flows

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-01-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
Indivior Pharmaceuticals, Inc. cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $317,000,000.00Net income → Operating adjustments reconciliation: $31,000,000.00Deferred income taxes → Operating adjustments reconciliation: $35,000,000.00Stock-based compensation → Operating adjustments reconciliation: $28,000,000.00Loss on debt extinguishment → Operating adjustments reconciliation: $18,000,000.00Impairment of tangible and intangible assets → Operating adjustments reconciliation: $8,000,000.00Depreciation and amortization → Operating adjustments reconciliation: $5,000,000.00Amortization of right-of-use assets → Operating adjustments reconciliation: $4,000,000.00Impact from foreign exchange movements → Operating adjustments reconciliation: $4,000,000.00Current inventories → Operating adjustments reconciliation: $4,000,000.00Amortization of debt issuance costs → Operating adjustments reconciliation: $1,000,000.00Remaining operating cash flows, net (calculated) → Operating adjustments reconciliation: $1,000,000.00Operating adjustments reconciliation → Other current and noncurrent liabilities: $62,000,000.00Operating adjustments reconciliation → Accrued legal and settlement expenses: $38,000,000.00Operating adjustments reconciliation → Other current and noncurrent assets: $20,000,000.00Operating adjustments reconciliation → Accounts receivable: $19,000,000.00Sales and maturities of debt securities → investing reconciliation: $13,000,000.00investing reconciliation → Purchases of property and equipment: $41,000,000.00investing reconciliation → Purchases of investments in debt securities: $12,000,000.00investing reconciliation → Remaining investing cash flows, net (calculated): $1,000,000.00Net cash used in financing activities → financing reconciliation: $166,000,000.00Proceeds from debt, net → financing reconciliation: $489,000,000.00Other → financing reconciliation: $6,000,000.00financing reconciliation → Repayments of debt: $333,000,000.00financing reconciliation → Cash paid for repurchases of common stock: $302,000,000.00financing reconciliation → Settlement of equity awards: $21,000,000.00financing reconciliation → Transaction costs related to debt refinancing: $5,000,000.00Net cash used in investing activities → investing reconciliation: $41,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $195,000,000.00Net cash from operating activities → Cash sources and uses: $317,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $305,000,000.00Cash sources and uses → Net cash used in investing activities: $41,000,000.00Cash sources and uses → Net cash used in financing activities: $166,000,000.00Net income: $348,000,000.00Net income+$348.00 MDepreciation and amortization: $5,000,000.00Depreciation & amortization+$5.00 MAmortization of right-of-use assets: $4,000,000.00Operating lease amortization+$4.00 MStock-based compensation: $28,000,000.00Stock-based compensation+$28.00 MImpairment of tangible and intangible assets: $8,000,000.00Asset impairments+$8.00 MLoss on debt extinguishment: $18,000,000.00Debt extinguishment gain & loss+$18.00 MUnrealized loss on equity investments: -$0.00Deferred income taxes: $35,000,000.00Deferred income taxes+$35.00 MImpact from foreign exchange movements: $4,000,000.00FX transaction gain & loss+$4.00 MAmortization of debt issuance costs: $1,000,000.00Debt issuance cost amortization+$1.00 MOther adjustments, net: -$0.00Accounts receivable: -$19,000,000.00Accounts receivable−$19.00 MCurrent inventories: $4,000,000.00Inventories+$4.00 MOther current and noncurrent assets: -$20,000,000.00Other operating assets−$20.00 MAccrued legal and settlement expenses: -$38,000,000.00Accrued legal and settlement expenses−$38.00 MOther current and noncurrent liabilities: -$62,000,000.00Other operating liabilities−$62.00 MRemaining operating cash flows, net (calculated): $1,000,000.00Remaining operating (calculated)+$1.00 MNet cash from operating activities: $317,000,000.00Operating cash+$317.00 MOperating adjustments reconciliation: $139,000,000.00Proceeds from the issuance of common stock: $0.00Cash paid for repurchases of common stock: -$302,000,000.00Common stock repurchases−$302.00 MProceeds from debt, net: $489,000,000.00Long-term debt issued+$489.00 MRepayments of debt: -$333,000,000.00Long-term debt repaid−$333.00 MOther: $6,000,000.00Other financing, net+$6.00 MTransaction costs related to debt refinancing: -$5,000,000.00Debt issuance costs−$5.00 MSettlement of equity awards: -$21,000,000.00Stock-award tax withholding−$21.00 MNet cash used in financing activities: -$166,000,000.00. Cash required to fund net payments.Financing cash−$166.00 Mfinancing reconciliation: $661,000,000.00Purchases of property and equipment: -$41,000,000.00PP&E purchases−$41.00 MPurchases of in-process research and development and intangible assets: -$0.00Purchases of investments in debt securities: -$12,000,000.00HTM securities purchases−$12.00 MSales and maturities of debt securities: $13,000,000.00HTM sales & maturities+$13.00 MRemaining investing cash flows, net (calculated): -$1,000,000.00Remaining investing (calculated)−$1.00 MNet cash used in investing activities: -$41,000,000.00. Cash required to fund net payments.Investing cash−$41.00 Minvesting reconciliation: $54,000,000.00Cash sources and uses: $512,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $195,000,000.00Beginning cash$195.00 MEnding cash: Cash, cash equivalents, and restricted cash: $305,000,000.00Ending cash$305.00 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$276.00 MOperating cash − cash spent on PP&ECash flow / Net income0.91×Operating cash flow ÷ net incomeNet cash change+$110.00 MEnding cash − beginning cash
Chart details

Indivior Pharmaceuticals, Inc. cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026

Cash flows for Jan 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
195,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
317,000,000 US dollars. Net cash provided. The remaining amount is calculated by subtracting the other displayed items from the operating total. The filing's tagged operating lines do not add up to the operating total; this is the difference. It may combine inflows and outflows.
Net income
348,000,000 US dollars
Depreciation and amortization
5,000,000 US dollars
Amortization of right-of-use assets
4,000,000 US dollars
Stock-based compensation
28,000,000 US dollars
Impairment of tangible and intangible assets
8,000,000 US dollars
Loss on debt extinguishment
18,000,000 US dollars
Unrealized loss on equity investments
0 US dollars
Deferred income taxes
35,000,000 US dollars
Impact from foreign exchange movements
4,000,000 US dollars
Amortization of debt issuance costs
1,000,000 US dollars
Other adjustments, net
0 US dollars
Accounts receivable
negative 19,000,000 US dollars
Current inventories
4,000,000 US dollars
Other current and noncurrent assets
negative 20,000,000 US dollars
Accrued legal and settlement expenses
negative 38,000,000 US dollars
Other current and noncurrent liabilities
negative 62,000,000 US dollars
Remaining operating cash flows, net (calculated)
1,000,000 US dollars
Investing activities
negative 41,000,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the investing total. The filing's tagged investing lines do not add up to the investing total; this is the difference. It may combine inflows and outflows.
Purchases of property and equipment
negative 41,000,000 US dollars
Purchases of in-process research and development and intangible assets
0 US dollars
Purchases of investments in debt securities
negative 12,000,000 US dollars
Sales and maturities of debt securities
13,000,000 US dollars
Remaining investing cash flows, net (calculated)
negative 1,000,000 US dollars
Financing activities
negative 166,000,000 US dollars. Net cash used.
Proceeds from the issuance of common stock
0 US dollars
Cash paid for repurchases of common stock
negative 302,000,000 US dollars
Proceeds from debt, net
489,000,000 US dollars
Repayments of debt
negative 333,000,000 US dollars
Other
6,000,000 US dollars
Transaction costs related to debt refinancing
negative 5,000,000 US dollars
Settlement of equity awards
negative 21,000,000 US dollars
Operating adjustment reconciliation
139,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
financing gross reconciliation
661,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing displayed reconciliation
54,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
Exchange-rate effect
0 US dollars
Ending cash on Sep 30, 2026
305,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
512,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
110,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.91×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
317,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
41,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
276,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $317.00M of net income directly to operating cash and $31.00M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 317,000,000 US dollars minus 41,000,000 US dollars equals 276,000,000 US dollars.
Indivior Pharmaceuticals, Inc. (INDV) FY2026 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!